Objective: To evaluate the efficacy and safety of Zhibitai combined with atorvastatin on blood lipid and inflammation. Method: This was a retrospective study which included eighty-five patients with coronary heart disease (CHD) with dyslipidemia in the Affiliated Hospital of Hebei University, from July 2022 to January 2024. They were divided into two groups according to the random number table, the atorvastatin monotherapy group (n=37) and the combination treatment group (n=48). Observation of changes in blood lipids, inflammatory mediators and incidence of adverse reactions were noted. Results: The levels of TC, LDL-C, and TG in both groups were significantly reduced compared to pre-treatment (p<0.05. The combination treatment group showed more significant decrease than the monotherapy group at four and 12 weeks of treatment (p<0.05); Both groups showed significant increase in HDL-C levels compared to pre-treatment (p<0.05), at week 12 of treatment, the combination treatment group showed more significant increase compared to the monotherapy group (p<0.05); Both groups can significantly reduce hs-CRP and IL-6(p<0.05); IL-6 was significantly reduced in the combination treatment group at four and 12 weeks of treatment compared to the monotherapy group (p<0.05); The decrease in hs-CRP in the combination treatment group was more significant than the monotherapy group after 12 weeks of treatment (p<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (p>0.05). Conclusion: Zhibitai combined with atorvastatin can effectively improve the lipid composition of patients with CHD, reduce inflammatory reactions, and have good safety.